Technology News and Research

RSS

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

BioVentrix announces completion of enrollment in PliCath HF human clinical trial

BioVentrix, developer of the PliCath HF System, today announced the achievement of a significant milestone - completion of enrollment in its pilot human clinical trial. PliCath HF is a novel device which enables Epicardial Catheter-based Ventricular Restoration (ECVR).

14 Nov 2011

Nile Therapeutics third quarter net loss decreases to $1.1 million

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its third quarter financial results for 2011.

14 Nov 2011

First Edition: November 14, 2011

In today's headlines, reports about the Supreme Court's expected health law announcement; about where things stand with the super committee and its fast-approaching deadline; and other health policy news.

14 Nov 2011

Luminescent upconversion nanocrystals can detect cancer cells

Upconversion emission materials are ideal for bioimaging due to its effectiveness as contrast agents for the detection of cancer cells, more so when the background emission of non-cancerous tissues can be minimised. These materials could be used as biomarkers for luminescent labeling of cancerous cells. Opaque tissues can be turned into glassy, transparent substances by using these biomarkers which rely on near-infrared excitation.

14 Nov 2011

Former soldier develops app to save lives of burns victims

A former soldier has developed an app which could save the lives of burns victims, both in combat and in hospitals around the world.

14 Nov 2011

BSP completes HyperQ technology clinical research study on CAD

BSP Biological Signal Processing Ltd. (BSP), which develops and manufactures products for the non-invasive, accurate diagnosis of Coronary Artery Disease (CAD), recently announced the successful completion of a comprehensive clinical research study evaluating the performance of the company's HyperQ technology in diagnosing CAD.

14 Nov 2011

Sleep problems may increase risk of fibromyalgia among women

Researchers from Norway have uncovered an association between sleep problems and increased risk of fibromyalgia in women.

14 Nov 2011

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

14 Nov 2011

Penn-led team develops microelectronic device to map brain activity

A team of researchers co-led by the University of Pennsylvania has developed and tested a new high-resolution, ultra-thin device capable of recording brain activity from the cortical surface without having to use penetrating electrodes.

14 Nov 2011

Flexible brain implant could treat epileptic seizures

Researchers funded by the National Institutes of Health have developed a flexible brain implant that could one day be used to treat epileptic seizures. In animal studies, the researchers used the device - a type of electrode array that conforms to the brain's surface - to take an unprecedented look at the brain activity underlying seizures.

14 Nov 2011

IVI receives WHO prequalification for new oral cholera vaccine

Shanchol-, a new oral cholera vaccine developed through the International Vaccine Institute (IVI), an international organization established by the United Nations and based in Seoul, recently received prequalification from the World Health Organization.

13 Nov 2011

New stem cell technique hopes to replace damaged cells in Parkinson's

Australian scientists have developed a new technique using stem cells, in the hope to replace damaged cells in Parkinson's disease. The technique could be developed for application in other degenerative conditions.

13 Nov 2011

Brazilian Ministry of Health, Bristol-Myers Squibb sign technology transfer agreement for Reyataz

Bristol-Myers Squibb Company today announced a technology transfer agreement with the Brazilian Ministry of Health to expand access to Reyataz (atazanavir sulfate) in Brazil.

13 Nov 2011

Medicaid update: Wis. approves big cuts; Wash. state lawsuit on ER visits; Kansas electronic medical records initiative

The Wisconsin Legislature's Republican-controlled state budget committee voted Thursday to approve about $225 million in Medicaid cuts expected to result in about 65,000 poor adults and children leaving health insurance programs, either because they would no longer be eligible or they could no longer afford coverage.

11 Nov 2011

Mutations make Staph more resistant to antibiotics

Infectious diseases specialists from Austin Health are working closely with Microbiologists from the University of Melbourne to understand how Staph is becoming resistant to all antibiotic therapies.

11 Nov 2011

Cultivating cells in sealed, sterile plastic bags

Using plasmas, sealed plastic bags can be modified at atmospheric pressure so that human cells can adhere to and reproduce on their walls. Cell culture bags of this kind are an important aid for research and clinical purposes and may eventually replace the Petri dishes used today.

11 Nov 2011

NeoStem third quarter revenues increase to $17.8 million

NeoStem, Inc., an international biopharmaceutical company with a focus on cell based therapeutics development, today reported third quarter results and recent progress in its business.

11 Nov 2011

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.

11 Nov 2011

Worm model to evaluate drugs for Parkinson's disease

Researchers at The University of Texas at Austin have devised a simple test, using dopamine-deficient worms, for identifying drugs that may help people with Parkinson's disease.

11 Nov 2011